Genflow Biosciences Shares Jump 25% on Positive Dog Aging Gene Therapy Results - Share Talk

Genflow Biosciences Shares Jump 25% on Positive Dog Aging Gene Therapy Results

Update on Animal Health Program

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF), the only publicly listed longevity company in Europe, is pleased to provide an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.

Genflow’s proprietary centenarian SIRT6 gene therapy has now been administered for the second time in its ongoing randomized, controlled trial involving 28 beagles aged 10 years and older. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects observed, while control animals remained untreated. The repeat administration has again demonstrated an excellent safety and tolerability profile, marking a key milestone in the study. The dogs are in a follow-up period expected to conclude in January 2026.

This successful second administration underscores the robustness of Genflow’s gene therapy platform and its potential applicability beyond human health. The SIRT6 gene, sourced from human centenarians, plays a vital role in DNA repair, metabolic regulation, and resistance to age-related decline. By leveraging this unique gene variant, Genflow aims to introduce a new class of longevity-based treatments into the multi-billion-dollar global animal health market, targeting improved healthspan, vitality, and lifespan in companion and livestock animals.

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: “We’re very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we’re seeing from established players in the animal health industry. The animal health market represents an attractive near-term commercial opportunity for Genflow, complementing our core human longevity programs while showcasing the broader potential of our gene therapy platform.”

With safety confirmed in repeat administration, Genflow will continue to advance its animal health initiative toward the next stage of clinical evaluation and partnership development. The Company remains committed to creating value for shareholders through innovation, collaboration, and leadership in the emerging field of genetic longevity therapeutics.

Contacts

Genflow Biosciences

Harbor Access                         

Dr Eric Leire, CEO

Jonathan Paterson, Investor Relations

+32-477-495-881

+1 475 477 9401

Jonathan.Paterson@Harbor-access.com


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned